Fierce Biotech1 min read
saveKairos seizes moment to push prostate cancer prospect into earlier setting
Kairos Pharma is moving prostate cancer prospect ENV-105 into an earlier line of treatment in response to midphase survival data.
Kairos Pharma is moving prostate cancer prospect ENV-105 into an earlier line of treatment in response to midphase survival data.
comments(0)
5-min edit window · permanent after that